eszopiclone + fluoxetine

Eszopiclone + fluoxetine is a combination therapy involving two small molecule drugs: eszopiclone, a nonbenzodiazepine hypnotic (marketed as Lunesta), and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant (marketed as Prozac). This combination has been studied for the treatment of patients with insomnia coexisting with major depressive disorder. Eszopiclone acts primarily by modulating the gamma-aminobutyric acid receptor subunit alpha-1 to promote sleep onset and maintenance[2]. Fluoxetine increases synaptic serotonin levels by inhibiting its reuptake, thereby exerting antidepressant effects[6]. Clinical studies have shown that this combination can result in rapid and sustained improvement in sleep parameters, faster onset of antidepressant response, and greater magnitude of antidepressant effect compared to monotherapy. The regimen is generally well tolerated but may increase the risk of central nervous system depression due to additive sedative effects[1][3][5].

Brand names

Lunesta + Prozac

Other names

eszopiclone and fluoxetineeszopiclone/fluoxetine co-therapy